Randomised controlled trial: Community screening for heart failure: ready for prime time?

Evidence-Based Medicine

Volumn 19, Issue 3, 2014, Pages 107-

  Doughty, Robert Neil ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DIASTOLIC DYSFUNCTION; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MASS SCREENING; NOTE; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84901931638     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/eb-2013-101511     Document Type: Note

References (3)

1. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-63. (Pubitemid 38364624)
2. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
3. Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association Heart Failure staging criteria in the community. Circulation 2007;115:1563-70. (Pubitemid 46648641)